Cargando…
Identification of hepatocellular carcinoma prognostic markers based on 10-immune gene signature
Background: Due to the heterogeneity of hepatocellular carcinoma (HCC), hepatocelluarin-associated differentially expressed genes were analyzed by bioinformatics methods to screen the molecular markers for HCC prognosis and potential molecular targets for immunotherapy. Methods: RNA-seq data and cli...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Portland Press Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457228/ https://www.ncbi.nlm.nih.gov/pubmed/32789471 http://dx.doi.org/10.1042/BSR20200894 |
_version_ | 1783575958789292032 |
---|---|
author | Zhao, Kaifei Xu, Lin Li, Feng Ao, Jin Jiang, Guojun Shi, Rongshu Chen, Fang Luo, Qing |
author_facet | Zhao, Kaifei Xu, Lin Li, Feng Ao, Jin Jiang, Guojun Shi, Rongshu Chen, Fang Luo, Qing |
author_sort | Zhao, Kaifei |
collection | PubMed |
description | Background: Due to the heterogeneity of hepatocellular carcinoma (HCC), hepatocelluarin-associated differentially expressed genes were analyzed by bioinformatics methods to screen the molecular markers for HCC prognosis and potential molecular targets for immunotherapy. Methods: RNA-seq data and clinical follow-up data of HCC were downloaded from The Cancer Genome Atlas (TCGA) database. Multivariate Cox analysis and Lasso regression were used to identify robust immunity-related genes. Finally, a risk prognosis model of immune gene pairs was established and verified by clinical features, test set and Gene Expression Omnibus (GEO) external validation set. Results: A total of 536 immune-related gene (IRGs) were significantly associated with the prognosis of patients with HCC. Ten robust IRGs were finally obtained and a prognostic risk prediction model was constructed by feature selection of Lasso. The risk score of each sample is calculated based on the risk model and is divided into high risk group (Risk-H) and low risk group (Risk-L). Risk models enable risk stratification of samples in training sets, test sets, external validation sets, staging and subtypes. The area under the curve (AUC) in the training set and the test set were all >0.67, and there were significant overall suvival (OS) differences between the Risk-H and Risk-L samples. Compared with the published four models, the traditional clinical features of Grade, Stage and Gender, the model performed better on the risk prediction of HCC prognosis. Conclusion: The present study constructed 10-gene signature as a novel prognostic marker for predicting survival in patients with HCC. |
format | Online Article Text |
id | pubmed-7457228 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Portland Press Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-74572282020-09-04 Identification of hepatocellular carcinoma prognostic markers based on 10-immune gene signature Zhao, Kaifei Xu, Lin Li, Feng Ao, Jin Jiang, Guojun Shi, Rongshu Chen, Fang Luo, Qing Biosci Rep Bioinformatics Background: Due to the heterogeneity of hepatocellular carcinoma (HCC), hepatocelluarin-associated differentially expressed genes were analyzed by bioinformatics methods to screen the molecular markers for HCC prognosis and potential molecular targets for immunotherapy. Methods: RNA-seq data and clinical follow-up data of HCC were downloaded from The Cancer Genome Atlas (TCGA) database. Multivariate Cox analysis and Lasso regression were used to identify robust immunity-related genes. Finally, a risk prognosis model of immune gene pairs was established and verified by clinical features, test set and Gene Expression Omnibus (GEO) external validation set. Results: A total of 536 immune-related gene (IRGs) were significantly associated with the prognosis of patients with HCC. Ten robust IRGs were finally obtained and a prognostic risk prediction model was constructed by feature selection of Lasso. The risk score of each sample is calculated based on the risk model and is divided into high risk group (Risk-H) and low risk group (Risk-L). Risk models enable risk stratification of samples in training sets, test sets, external validation sets, staging and subtypes. The area under the curve (AUC) in the training set and the test set were all >0.67, and there were significant overall suvival (OS) differences between the Risk-H and Risk-L samples. Compared with the published four models, the traditional clinical features of Grade, Stage and Gender, the model performed better on the risk prediction of HCC prognosis. Conclusion: The present study constructed 10-gene signature as a novel prognostic marker for predicting survival in patients with HCC. Portland Press Ltd. 2020-08-28 /pmc/articles/PMC7457228/ /pubmed/32789471 http://dx.doi.org/10.1042/BSR20200894 Text en © 2020 The Author(s). https://creativecommons.org/licenses/by/4.0/ This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY). |
spellingShingle | Bioinformatics Zhao, Kaifei Xu, Lin Li, Feng Ao, Jin Jiang, Guojun Shi, Rongshu Chen, Fang Luo, Qing Identification of hepatocellular carcinoma prognostic markers based on 10-immune gene signature |
title | Identification of hepatocellular carcinoma prognostic markers based on 10-immune gene signature |
title_full | Identification of hepatocellular carcinoma prognostic markers based on 10-immune gene signature |
title_fullStr | Identification of hepatocellular carcinoma prognostic markers based on 10-immune gene signature |
title_full_unstemmed | Identification of hepatocellular carcinoma prognostic markers based on 10-immune gene signature |
title_short | Identification of hepatocellular carcinoma prognostic markers based on 10-immune gene signature |
title_sort | identification of hepatocellular carcinoma prognostic markers based on 10-immune gene signature |
topic | Bioinformatics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457228/ https://www.ncbi.nlm.nih.gov/pubmed/32789471 http://dx.doi.org/10.1042/BSR20200894 |
work_keys_str_mv | AT zhaokaifei identificationofhepatocellularcarcinomaprognosticmarkersbasedon10immunegenesignature AT xulin identificationofhepatocellularcarcinomaprognosticmarkersbasedon10immunegenesignature AT lifeng identificationofhepatocellularcarcinomaprognosticmarkersbasedon10immunegenesignature AT aojin identificationofhepatocellularcarcinomaprognosticmarkersbasedon10immunegenesignature AT jiangguojun identificationofhepatocellularcarcinomaprognosticmarkersbasedon10immunegenesignature AT shirongshu identificationofhepatocellularcarcinomaprognosticmarkersbasedon10immunegenesignature AT chenfang identificationofhepatocellularcarcinomaprognosticmarkersbasedon10immunegenesignature AT luoqing identificationofhepatocellularcarcinomaprognosticmarkersbasedon10immunegenesignature |